FeedworthyAI
Back to feed
Biotech / Medtech Archives | citybiznews

Prolium Bioscience Doses First Patient in Global Phase 1/2 Systemic Sclerosis Study of PRO-203

Monday, June 22, 2026Sobeida DiloneView original
Prolium Bioscience Doses First Patient in Global Phase 1/2 Systemic Sclerosis Study of PRO-203

Prolium Bioscience, Inc. (Prolium), a clinical stage biotechnology company, today announced that the first patient has been dosed in a... Read More

The post Prolium Bioscience Doses First Patient in Global Phase 1/2 Systemic Sclerosis Study of PRO-203 appeared first on citybiz.